NM_004453.3(ETFDH):c.34G>C (p.Ala12Pro) AND Glutaric aciduria, type 2

Clinical significance:Uncertain significance (Last evaluated: Sep 21, 2017)

Review status:1 star out of maximum of 4 stars

criteria provided, single submitter

Based on:
1 submission [Details]
Record status:

Allele description [Variation Report for NM_004453.3(ETFDH):c.34G>C (p.Ala12Pro)]

NM_004453.3(ETFDH):c.34G>C (p.Ala12Pro)

ETFDH:electron transfer flavoprotein dehydrogenase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Genomic location:
Preferred name:
NM_004453.3(ETFDH):c.34G>C (p.Ala12Pro)
  • NC_000004.12:g.158672490G>C
  • NG_007078.2:g.5149G>C
  • NM_004453.3:c.34G>C
  • NP_004444.2:p.Ala12Pro
  • NC_000004.11:g.159593642G>C
Protein change:
Molecular consequence:
  • NM_004453.3:c.34G>C - missense variant - [Sequence Ontology: SO:0001583]


Glutaric aciduria, type 2 (MADD)
GA II; GLUTARIC ACIDURIA II; Multiple Acyl Coenzyme A Dehydrogenase Deficiency
MedGen: C0268596; Orphanet: 26791; OMIM: 231680

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV000828332Invitaecriteria provided, single submitter
Uncertain significance
(Sep 21, 2017)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing



Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11.

PubMed [citation]

Details of each submission

From Invitae, SCV000828332.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)


This sequence change replaces alanine with proline at codon 12 of the ETFDH protein (p.Ala12Pro). The alanine residue is moderately conserved and there is a small physicochemical difference between alanine and proline. This variant also falls at the last nucleotide of exon 1 of the ETFDH coding sequence, which is part of the consensus splice site for this exon. Nucleotide substitutions within the consensus splice site are relatively common causes of aberrant splicing (PMID: 17576681, 9536098). This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with ETFDH-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Mar 30, 2019

Support Center